Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2008 Oct;23(10):1238-9.
doi: 10.1177/0883073808321764.

Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex

Mary Kay Koenig  1 , Ian J Butler, Hope Northrup
Affiliations
Case Reports

Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex

Mary Kay Koenig et al. J Child Neurol. 2008 Oct.

Abstract

The authors present a 21-year-old woman who has been receiving rapamycin for 5 months for bilateral subependymal giant cell astrocytomas. The patient was started at a dose of 0.2 mg/kg/day. Levels were maintained between 11 and 13 ng/mL. Magnetic resonance imaging of the brain 2(1/2) months after initiating rapamycin demonstrated a decrease in size of both astrocytomas (11 to 7.5 mm on the right and 8 to 5 mm on the left). Further studies are needed with prolonged observation to confirm these findings, determine the length of necessary treatment, and evaluate recurrence risk after discontinuation of rapamycin.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Magnetic resonance imaging of the brain, coronal, T1, postcontrast. A, Pretreatment image with right-sided astrocytoma measuring 11 mm and left-sided astrocytoma measuring 8 mm. B, Posttreatment image with right-sided astrocytoma measuring 8 mm and left-sided astrocytoma measuring 5 mm.
See this image and copyright information in PMC

References

    1. Kenerson H, Dundon TA, Yeung RS. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res. 2005;57:67–75. - PubMed
    1. Rauktys A, Lee N, Lee L, Dabora SL. Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model. BMC Dermatol. 2008;8:1–9. - PMC - PubMed
    1. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358:140–151. - PMC - PubMed
    1. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006;59:490–498. - PubMed

Publication types

MeSH terms